WO2007043050A3 - Bioconjugates comprising sulfated polysaccharides and their uses - Google Patents
Bioconjugates comprising sulfated polysaccharides and their uses Download PDFInfo
- Publication number
- WO2007043050A3 WO2007043050A3 PCT/IL2006/001178 IL2006001178W WO2007043050A3 WO 2007043050 A3 WO2007043050 A3 WO 2007043050A3 IL 2006001178 W IL2006001178 W IL 2006001178W WO 2007043050 A3 WO2007043050 A3 WO 2007043050A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bioconjugates
- polypeptide
- bioactive
- sulfate
- sulfated polysaccharides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Abstract
The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can be a heparin-binding polypeptide or a positively-charged polypeptide and is preferably a peptide growth factor or a cytokine. The bioconjugates serve as delivery systems for sustained release of the bioactive polypeptides. Also provided are pharmaceutical compositions comprising the bioconjugates or comprising the sulfated polysaccharides.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14187527.8A EP2902040B1 (en) | 2005-10-11 | 2006-10-15 | Bioconjugates comprising sulfated polysaccharides and their use |
EP06809754A EP1933879A2 (en) | 2005-10-11 | 2006-10-15 | Bioconjugates comprising sulfated polysaccharides and their uses |
IL190719A IL190719A (en) | 2005-10-11 | 2008-04-08 | Bioconjugates comprising sulfated polysaccharides and their uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/374,279 | 2005-10-11 | ||
US11/374,279 US7517856B2 (en) | 2005-10-11 | 2005-10-11 | Bioconjugates comprising sulfated polysaccharides and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007043050A2 WO2007043050A2 (en) | 2007-04-19 |
WO2007043050A3 true WO2007043050A3 (en) | 2008-07-24 |
Family
ID=37667182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2006/001178 WO2007043050A2 (en) | 2005-10-11 | 2006-10-15 | Bioconjugates comprising sulfated polysaccharides and their uses |
Country Status (3)
Country | Link |
---|---|
US (2) | US7517856B2 (en) |
EP (2) | EP1933879A2 (en) |
WO (1) | WO2007043050A2 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517856B2 (en) * | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
EP2025687A1 (en) * | 2007-07-23 | 2009-02-18 | Istituto Scientifico di Chimica E Biochimica "G Ronzoni | Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby |
IL187707A0 (en) * | 2007-11-27 | 2008-11-03 | Univ Ben Gurion | Alginate scaffold in hepatectomy |
WO2009070698A1 (en) * | 2007-11-29 | 2009-06-04 | The Trustees Of Columbia University In The City Of New York | Microsphere skin treatment |
US8343942B2 (en) | 2008-04-04 | 2013-01-01 | University Of Utah Research Foundation | Methods for treating interstitial cystitis |
KR101594552B1 (en) | 2008-04-04 | 2016-02-17 | 유니버시티 오브 유타 리서치 파운데이션 | Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof |
CA2750223A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
EP2391646B1 (en) | 2009-01-28 | 2016-08-10 | Smartcells, Inc. | Crystalline insulin-conjugates |
JP2012516340A (en) | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | Synthetic conjugates and uses thereof |
EA027757B1 (en) | 2009-01-28 | 2017-08-31 | Смартселлз, Инк. | Conjugate for controlled insulin delivery |
WO2010107519A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
US8569231B2 (en) | 2009-03-20 | 2013-10-29 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
IT1397247B1 (en) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | NEW REGULATORY AGENTS OF CYTOKINIC ACTIVITY |
US20120264689A1 (en) * | 2009-10-07 | 2012-10-18 | Genogen, Inc. | Methods and compositions for skin regeneration |
US8795727B2 (en) | 2009-11-09 | 2014-08-05 | Spotlight Technology Partners Llc | Fragmented hydrogels |
US9700650B2 (en) | 2009-11-09 | 2017-07-11 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
WO2011078990A1 (en) * | 2009-12-14 | 2011-06-30 | Benaroya Research Institute At Virginia Mason | Hydrogels comprising hyaluronan and at least one t cell induction agent |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
PT3536333T (en) * | 2010-01-04 | 2022-11-11 | Mapi Pharma Ltd | Depot system comprising glatiramer acetate |
WO2011121036A2 (en) * | 2010-03-30 | 2011-10-06 | Vib Vzw | Induction of arteriogenesis using specific factors or by cell therapy with polarized myeloid cells |
WO2011130697A2 (en) | 2010-04-16 | 2011-10-20 | Momenta Pharmaceuticals, Inc. | Tissue targeting |
WO2012003479A2 (en) * | 2010-07-01 | 2012-01-05 | Regenerative Research Foundation | Methods for culturing undifferentiated cells using sustained release compositions |
CA2805739A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
JP2013535467A (en) | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | Recombinantly expressed insulin polypeptide and uses thereof |
JP2013541500A (en) | 2010-07-28 | 2013-11-14 | スマートセルズ・インコーポレイテツド | Recombinant lectins, binding site modified lectins and their uses |
EP2688402B1 (en) | 2011-03-23 | 2018-10-24 | University of Utah Research Foundation | Means for treating or preventing urological inflammation |
EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
KR101388785B1 (en) * | 2011-07-25 | 2014-04-23 | 가톨릭대학교 산학협력단 | Drug Complex Consisting of Protein or Peptide Drug and Sulfate Groups-Containing Polysaccharides for Stable and Continuous drug delivery |
US9731046B2 (en) | 2012-02-21 | 2017-08-15 | Ben Gurion University Of The Negev Research And Development Authority | Hydrogel system comprising spatially separated bioactive polypeptides |
US10195252B2 (en) | 2012-08-03 | 2019-02-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Recruitment of mensenchymal cells using controlled release systems |
PT2916881T (en) * | 2012-11-07 | 2020-03-17 | Eth Zuerich | Sulfated alginate hydrogels for cell culture and therapy |
US9931404B2 (en) * | 2013-06-10 | 2018-04-03 | Case Western Reserve University | Glycosaminoglycans for chemokine drug delivery |
MX2015017235A (en) | 2013-06-13 | 2017-05-04 | Orgenesis Ltd | Cell populations, methods of transdifferention and methods of use thereof. |
BR112016007176A2 (en) | 2013-10-04 | 2018-01-23 | Merck Sharp & Dohme | conjugate, composition, uses of a conjugate and composition, and method for treating an individual having diabetes |
WO2015070172A1 (en) * | 2013-11-08 | 2015-05-14 | The Regents Of The University Of Michigan | Efficient aqueous encapsulation and controlled release of bioactive agents |
EP3012269A1 (en) | 2014-10-20 | 2016-04-27 | Erhard Hofer | Cytokine-like 1 (CYTL1) protein and uses thereof |
MA41296A (en) | 2014-12-30 | 2017-11-07 | Orgenesis Ltd | TRANSDIFFERENTIATION PROCESSES AND METHODS FOR USING THE SAME |
KR20180104646A (en) * | 2016-01-07 | 2018-09-21 | 비.지. 네게브 테크놀로지즈 앤드 애플리케이션스 리미티드, 엣 벤-구리온 유니버시티 | Compositions and methods for establishing immune tolerance |
WO2017175229A1 (en) * | 2016-04-07 | 2017-10-12 | B.G. Negev Technologies And Applications Ltd. | Polysaccharide compositions and uses thereof |
WO2018053111A1 (en) | 2016-09-15 | 2018-03-22 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
CN106435831B (en) * | 2016-09-23 | 2018-07-06 | 青岛大学 | A kind of preparation method of the sodium alginate nano fiber based on self-assembly process |
CN110382052A (en) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | The copaxone store system of multiple sclerosis for therapeutic advance type form |
WO2018207179A1 (en) | 2017-05-08 | 2018-11-15 | Orgenesis Ltd. | Transdifferentiated cell populations and methods of use thereof |
US11389545B2 (en) * | 2018-01-09 | 2022-07-19 | Aqua Regenerative Therapies Llc | Bioactive nanoparticles and methods for making same |
WO2019183634A1 (en) * | 2018-03-23 | 2019-09-26 | Inscopix, Inc. | Reagent coated lenses |
CN109908359B (en) * | 2019-04-21 | 2022-04-29 | 西北工业大学 | Multi-drug staged continuous controlled release drug delivery system and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012464A1 (en) * | 1988-06-14 | 1989-12-28 | Massachusetts Institute Of Technology | Controlled release systems containing heparin and growth factors |
WO1999021588A1 (en) * | 1997-10-28 | 1999-05-06 | Cancer Research Campaign Technology Limited | Heparin-binding growth factor derivatives |
WO2000064481A1 (en) * | 1999-04-22 | 2000-11-02 | Eidgenössische Technische Hochschule (ETH) | Controlled release of growth factors from heparin containing matrices |
WO2001066164A1 (en) * | 1999-04-22 | 2001-09-13 | Eidgenossisch Technische Hochschule Zurich | Modified protein matrices |
EP1886696A1 (en) * | 2006-08-03 | 2008-02-13 | Endotis Pharma | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4178361A (en) * | 1973-09-10 | 1979-12-11 | Union Corporation | Sustained release pharmaceutical composition |
US6388060B1 (en) * | 1998-11-06 | 2002-05-14 | Vascular Therapeutics Inc. | Process for the sulfation of uronic acid-containing polysaccharides |
US7517856B2 (en) * | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
-
2005
- 2005-10-11 US US11/374,279 patent/US7517856B2/en active Active
-
2006
- 2006-10-15 EP EP06809754A patent/EP1933879A2/en not_active Withdrawn
- 2006-10-15 EP EP14187527.8A patent/EP2902040B1/en active Active
- 2006-10-15 WO PCT/IL2006/001178 patent/WO2007043050A2/en active Application Filing
-
2007
- 2007-01-05 US US11/649,844 patent/US7642240B2/en active Active - Reinstated
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012464A1 (en) * | 1988-06-14 | 1989-12-28 | Massachusetts Institute Of Technology | Controlled release systems containing heparin and growth factors |
WO1999021588A1 (en) * | 1997-10-28 | 1999-05-06 | Cancer Research Campaign Technology Limited | Heparin-binding growth factor derivatives |
WO2000064481A1 (en) * | 1999-04-22 | 2000-11-02 | Eidgenössische Technische Hochschule (ETH) | Controlled release of growth factors from heparin containing matrices |
WO2001066164A1 (en) * | 1999-04-22 | 2001-09-13 | Eidgenossisch Technische Hochschule Zurich | Modified protein matrices |
EP1886696A1 (en) * | 2006-08-03 | 2008-02-13 | Endotis Pharma | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins |
Non-Patent Citations (1)
Title |
---|
SCHROEDER-TEFFT J A ET AL: "Collagen and heparin matrices for growth factor delivery", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 48, no. 1, 22 September 1997 (1997-09-22), pages 29 - 33, XP004125838, ISSN: 0168-3659 * |
Also Published As
Publication number | Publication date |
---|---|
EP2902040A1 (en) | 2015-08-05 |
US7517856B2 (en) | 2009-04-14 |
US20070081976A1 (en) | 2007-04-12 |
US7642240B2 (en) | 2010-01-05 |
EP1933879A2 (en) | 2008-06-25 |
US20070110814A1 (en) | 2007-05-17 |
EP2902040B1 (en) | 2022-03-23 |
WO2007043050A2 (en) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007043050A3 (en) | Bioconjugates comprising sulfated polysaccharides and their uses | |
WO2006096614A3 (en) | Angiogenic heparin binding peptide amphiphiles | |
WO2019075263A3 (en) | Methods and compositions for topical delivery | |
HK1221252A1 (en) | Hla-a1101-restricted wt1 peptide and pharmaceutical composition comprising the same hla-a1101 wt1 | |
EP2266590A3 (en) | Active agent delivery sytems and methods for protecting and administering active agents | |
WO2007022239A3 (en) | Pharmaceutical formulations for sustained drug delivery | |
PL1940381T3 (en) | Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate | |
EP1992645A4 (en) | Novel low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition and food composition each using same | |
WO2006051110A3 (en) | Stable formulations of insulinoptropic peptides | |
EP2548884A3 (en) | Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system | |
WO2008015249A3 (en) | Cosmetic or pharmaceutical composition containing hyaluronic acid | |
WO2010048275A3 (en) | Lyophilized recombinant vwf formulations | |
PL2985026T3 (en) | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | |
IL196674A (en) | Exendin fusion proteins, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments | |
SE0300207D0 (en) | New use and composition | |
WO2007057714A3 (en) | Pharmaceutical compositions comprising methotrexate | |
UA91208C2 (en) | Pharmaceutical composition comprising antimicrobial glycopeptide and cephalosporin for therapy of drug resistant infective conditions | |
IL181301A0 (en) | Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof | |
HK1121396A1 (en) | Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions pqs | |
WO2008118017A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
IL187781A0 (en) | Lkktet and/or lkktnt peptide compositions whice are lyophilized or in from capable of being lyophilized | |
ZA200806542B (en) | Hla-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same | |
WO2007044809A3 (en) | Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use | |
PL1951219T3 (en) | Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate | |
WO2007047426A3 (en) | Bioactive delivery matrix compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006809754 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 190719 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2006809754 Country of ref document: EP |